According to a new study, patients with atopic dermatitis (AD) are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus as opposed to dupilumab alone.
Inaugural Atopic Dermatitis Summit open for registration
Registration is open for the inaugural Atopic Dermatitis (AD) Summit. The virtual symposium will be held on Saturday, April 23, 2022, at 10:00 a.m. EDT.
Difamilast ointment shows efficacy in treating atopic dermatitis
A new study found difamilast ointment 1% to be safe and efficacious in the treatment of atopic dermatitis (AD).
Dupilumab-induced ocular surface disease more frequently associated with AD, study shows
According to a new study, dupilumab-induced ocular surface disease (DIOSD) appears to occur more frequently in patients with atopic dermatitis (AD) than in patients with other conditions being treated with the biologic.
